Value-Based Care for Gallstone Pancreatitis
Value-based care, or spending less money to achieve better health, should be the goal of all modern healthcare systems. Simply defined as the change in patient (or population) health outcomes divided by the cost to achieve the change, value is hard to measure and even more difficult to achieve.1 The benefit for patients, providers, hospitals, and society is clear: reduced cost for better outcomes, providers focusing on quality over quantity, and improving the economic sustainability of healthcare systems.
Metabolic syndrome (MetS) has been associated with the development of gallstone disease; however, the impact of MetS on common bile duct (CBD) stones from choledocholithiasis (CDL) and/or gallstone pancreatitis (GSP) after cholecystectomy is unknown.
We present a case of a 37-year-old man, previously diagnosed with leprosy that developed acute pancreatitis after starting the multibacillary polychemotherapy (PCT/MB). After a month of treatment and the discontinuation of the PCT/MB, the therapy was restarted and a new episode of AP occurred. Three months after this last episode, the PCT/MB was reintroduced, changing one of the medications and the patient had no recurrence of AP or other reactions. Therefore, it is important to take into account that there is a risk of acute pancreatitis in patients on multidrug therapy (MDT) for leprosy.PMID:34586307 | PMC:PMC8494489 | D...